Remedica is specialised in the development and supply of pharmaceutical products for out-licensing. It offers attractive out-licensing opportunities to companies throughout the globe in a wide range of therapeutic areas. The offered dossiers comply with all applicable international and European standards. Together with you, Remedica will work towards the most cost effective solution aiming to be a sustainable partner that offers tailored solutions according to your specific needs and requirements.

GENERIC
NAME
STRENGTH and
DOSAGE FORM
THERAPEUTIC CATEGORY DOSSIER
AVAILABILITY
ABACAVIR / LAMIVUDINE** 600mg/300mg
Film-coated tablets
Antivirals YES
ABIRATERONE ACETATE** 250mg and 500mg
Film-coated tablets
Antineoplastic
agents
YES
ACETYLSALICYLIC ACID 75mg
Gastro-resistant tablets
Antithrombotic
agents
Q3-2024
ACICLOVIR 200mg, 400mg,
800mg Tablets
Antivirals Q4-2024
ALLOPURINOL 100mg, 300mg
Tablets
Antigout Q2-2022
AMIODARONE 200mg Tablets Antiarrhythmics Q3-2024
AMITRIPTYLINE 10mg, 25mg
Film-coated tablets
Antidepressants Q2-2023
AMOXICILLIN 250mg, 500mg
Capsules, hard
Antibacterials YES
AMOXICILLIN 125mg/5ml,
250mg/5ml Powder for oral suspension
Antibacterials Q3-2024
AMOXICILLIN / CLAVULANIC ACID 875/125mg
Film-coated Tablets
Antibacterials Q3-2023
AMOXICILLIN / CLAVULANIC ACID 500mg/125mg Film-coated tablets Antibacterials Q3-2022
ANASTROZOLE ** 1mg Film-coated
tablets
Antineoplastic
agents
YES
APIXABAN
**
2.5mg, 5mg
Film-coated tablets
Antithrombotic
agents
Q1-2025
ATAZANAVIR ** 100mg,
150mg, 200mg, 300mg Capsules, hard
Antivirals YES
AZATHIOPRINE 50mg
Film-coated tablets
Immunosuppressants Q4-2022
AZITHROMYCIN 125mg,
250mg, 500mg Film-coated tablets
Antibacterial Q3-2023
BISACODYL 5mg
Gastro-resistant tablets
Laxatives Q1-2023
BROMAZEPAM 1.5mg,
3mg, 6mg Tablets
Anxiolytics Q3-2023
CALCIUM LACTATE PENTAHYDRATE 300mg
Tablets
Supplements Q4-2021
CAPECITABINE ** 150mg,
500mg Film-coated tablets
Antineoplastic
agents
YES
CARBAMAZEPINE 200mg
Tablets
Antiepileptics Q3-2022
CARBAMAZEPINE 400mg
Prolonged-release tablets
Antiepileptics Q1-2024
CARBIMAZOLE 5mg
Tablets
Antithyroid
agents
Q1-2023
CEFIXIME 200mg,
400mg Film-coated tablets
Antibacterials Q1-2024
CEFALEXIN 250mg,
500mg Capsules, hard
Antibacterials Q3-2023
CEFPODOXIME PROXETIL 100mg,
200mg Film-coated tablets
Antibacterials Q2-2024
CEFUROXIME 125mg,
250mg, 500mg Film-coated tablets
Antibacterial Q1-2023
CHLORPROMAZINE 25mg,
50mg,100mg Film-coated tablets
Antipsychotics Q1-2024
CINACALCET ** 30mg,
60mg, 90mg Film-coated tablets
Anti-parathyroid
agents
YES
CIPROFLOXACIN 250mg,
500mg, 750mg Film-coated tablets
Antibacterials Q3-2022
CLARITHROMYCIN 250mg,
500mg Film-coated tablets
Antibacterials YES
CLONAZEPAM 0.5mg,
2mg Tablets
Antiepileptics Q4-2023
CLOZAPINE 25mg,
100mg Film-coated tablets
Antipsychotics YES
DAPOXETINE HYDROCHLORIDE 30mg,
60mg Film-coated tablets
N/A Q4-2022
DARUNAVIR ** 75mg,
150mg, 300mg, 400mg, 600mg, 800mg
Film-coated tablets
Antivirals YES
DASATINIB ** 20mg,
50mg, 70mg, 80mg, 100mg, 140mg Film-coated tablets
Antineoplastic
agents
YES
DIAZEPAM 2mg,
5mg, 10mg Tablets
Anxiolytics Q4-2024
DICLOFENAC SODIUM 25mg,
50mg Gastro-resistant tablets
Antiinflammatory Q3-2022
DICLOFENAC SODIUM 100mg
Prolonged-release tablets
Antiinflammatory Q1-2025
DOLUTEGRAVIR 10mg,
25mg, 50mg Film-coated tablets
Antivirals Q4-2026
DONEPEZIL 5MG,
10mg, Film-coated tablets
Anti-dementia
agent
Q1-2025
DOXYCYLCINE 100mg
Film-coated tablets
Antibacterials Q3-2024
DOXYCYLCINE 100mg
Capsules, hard
Antibacterials Q4-2025
EFAVIRENZ / EMTRICITABINE / TENOFOVIR DISOPROXIL ** 600mg/200mg/245mg
Film-coated tablets
Antivirals YES
EMTRICITABINE / TENOFOVIR DISOPROXIL ** 200mg/245mg
Film-coated tablets
Antivirals YES
ENALAPRIL MALEATE 5mg,
10mg, 20mg Tablets
ACE
inhibitors
Q4-2021
ENTECAVIR ** 0.5mg,
1mg Film-coated tablets
Antivirals YES
ERLOTINIB ** 25mg,
50mg, 100mg, 150mg Film-coated tablets
Antineoplastic
agents
YES
ERYTHROMYCIN 125mg/5ml,
250mg/5ml Powder for oral suspension
Antibacterials Q2-2024
ERYTHROMYCIN 250mg,
500mg Film-coated tablets
Antibacterials Q2-2025
ESCITALOPRAM 5mg,
10mg, 20mg Film-coated tablets
Antidepressants Q4-2022
EXEMESTANE 25mg
Film-coated tablets
Antineoplastic
agents
YES
FAMOTIDINE 20mg,
40mg Film-coated tablets
Antiulcerants
& antireflux agents
Q2-2024
FERROUS FUMARATE 200mg
Film-coated tablets
Antianemic
preparations
Q3-2023
FERROUS FUMARATE / FOLIC
ACID
185mg/0.4mg,
310mg/0.35mg Film-coated tablets
Antianemic
preparations
Q3-2023
FEXOFENADINE 120mg,
180mg Tablets
Antihistamines Q4-2024
FUROSEMIDE 40mg
Tablets
Diuretics Q2-2025
GEFITINIB ** 250mg
Film-coated tablets
Antineoplastic
agents
YES
GRISEOFULVIN 125mg,
500mg Tablets
Antifungals Q4-2023
HYDRALAZINE 25mg
Film-coated tablets
Antihypertensives Q1-2023
HYOSCINE BUTYLBROMIDE 10mg
Coated tablets
Gastrointestinal
disorder drugs
Q4-2023
IBUPROFEN 200mg,
400mg, 600mg Film-coated tablets
Antiinflammatory
& antirheumatics
Q1-2022
IMATINIB ** 100mg,
400mg Film-coated tablets
Antineoplastic
agents
YES
IVABRADINE ** 5mg,
7.5mg Film-coated tablets
Antiischemic
preparation
YES
LAPATINIB ** 250mg
Film-coated tablets
Antineoplastic
agents
Q3-2021
LETROZOLE 2.5mg
Film-coated tablets
Antineoplastic
agents
Q1-2022
LEVODOPA / CARBIDOPA 250mg/25mg,
100mg/25mg, 100mg/10mg Tablets
Antiparkinsons
drugs
Q2-2023
LINAGLIPTIN** 5mg
Film-Coated Tablets
Diabetes
drugs
Q4-2024
LINAGLIPTIN / METFORMIN ** 2.5mg/850mg,
2.5mg/1000mg, 5mg/1000mg Film-Coated Tablets
Diabetes
drugs
Q4-2024
METFORMIN HYDROCHLORIDE 500mg,
850mg Film-coated tablets
Diabetes
drugs
Q1-2023
METHOTREXATE 2.5
mg Film-coated tablets
Antineoplastic
agents
YES
METRONIDAZOLE 200mg,
250mg, 400mg, 500mg Film-coated tablets
Antibacterials Q2-2025
METHYLDOPA 250
mg Film-coated tablets
Antihypertensives Q4-2022
NAPROXEN 250mg,
500mg Tablets
Antiinflammatory
& antirheumatics
Q2-2023
NIFEDIPINE 10mg
Film-coated tablets
Calcium
channel blockers
Q4-2024
NIFEDIPINE 20mg
Prolonged-release tablets
Calcium
channel blockers
Q4-2025
NORETHISTERONE 5mg
Tablets
Sex
hormones and modulators of the genital system
Q1-2023
PAZOPANIB (as hydrochloride) ** 200mg,
400mg Film-coated tablets
Antineoplastic
agents
YES
PHENOXYMETHYLPENICILLIN 800mg,
1000mg Film-coated tablets
Antibacterials YES
PREGABALIN 25mg,
75mg, 150mg, 300mg Capsules, hard
Antiepileptics Q3-2022
RASAGILINE ** 1mg
Tablets
Antiparkinsons
drugs
YES
RITONAVIR/ ATAZANAVIR (as sulfate) ** 100/200mg,
100/300mg Film-coated tablets
Antivirals Q4-2021
RIVAROXABAN 2.5mg,
10mg, 15mg, 20mg Film-coated tablets
Antithrombotic
agents
Q3-2021
SILDENAFIL 25mg,
50mg, 100mg Film-coated tablets
Erectile
dysfunction agents
Q4-2022
SITAGLIPTIN (as
Hydrochloride monohydrate)
25mg, 50mg,
100mg Film-coated tablets
Diabetes
drugs
YES
SITAGLIPTIN (as Hydrochloride monohydrate) / METFORMIN HYDROCHLORIDE 50mg/850mg,
50mg/1000mg Film-coated tablets
Diabetes
drugs
YES
SORAFENIB ** 200mg
Film-coated tablets
Antineoplastic
agents
YES
SPIRONOLACTONE 25mg,
100mg Film-coated tablets
Diuretics Q2-2023
SULPIRIDE 50mg,
200mg Tablets
Antipsychotics Q1-2024
SUMATRIPTAN 50mg,
100mg Film-coated Tablets
Analgesics Q2-2023
SUNITINIB ** 12.5mg,
25mg, 37.5mg, 50mg Capsules, hard
Antineoplastic
agents
YES
TAMOXIFEN 10mg,
20mg Tablets
Antineoplastic
agents
Q1-2024
TENOFOVIR DISOPROXIL ** 123mg,
163mg, 204mg, 245mg Film-coated tablets
Antivirals YES
TERBINAFINE 250mg
Tablets
Antifungals YES
TICAGLEROR 60mg, 90mg
Film-coated tablets
Antithrombotic
agents
Q1-2022
TINIDAZOLE 500mg
Film-coated tablets
Antibacterials Q4-2024
VERAPAMIL 40mg,
80mg Coated tablets
Calcium
channel blockers
Q3-2025
GENERIC
NAME
STRENGTH and
DOSAGE FORM
THERAPEUTIC CATEGORY DOSSIER
AVAILABILITY
ABACAVIR / LAMIVUDINE** 600mg/300mg
Film-coated tablets
Antivirals YES
ABIRATERONE ACETATE** 250mg and 500mg
Film-coated tablets
Antineoplastic
agents
YES
ACETYLSALICYLIC ACID 75mg
Gastro-resistant tablets
Antithrombotic
agents
Q3-2024
ACICLOVIR 200mg, 400mg,
800mg Tablets
Antivirals Q4-2024
ALLOPURINOL 100mg, 300mg
Tablets
Antigout Q2-2022
AMIODARONE 200mg Tablets Antiarrhythmics Q3-2024
AMITRIPTYLINE 10mg, 25mg
Film-coated tablets
Antidepressants Q2-2023
AMOXICILLIN 250mg, 500mg
Capsules, hard
Antibacterials YES

*Patent Information: Availability of products is subject to patent restrictions in countries where applicable patents are in effect.
**Outlicensing to certain terrotories is subject to possible pre-existing Remedica’s contractual obligations with other parties.